ENDRA Life Sciences Inc. (NDRA)
3.13
-0.55 (-14.95%)
At close: Apr 14, 2025, 3:59 PM
3.18
1.60%
After-hours: Apr 14, 2025, 07:59 PM EDT
-14.95% (1D)
| Bid | 3.05 |
| Market Cap | 1.76M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.51M |
| EPS (ttm) | -56.94 |
| PE Ratio (ttm) | -0.05 |
| Forward PE | -0.01 |
| Analyst | Buy |
| Ask | 3.31 |
| Volume | 93,764 |
| Avg. Volume (20D) | 36,293 |
| Open | 3.61 |
| Previous Close | 3.68 |
| Day's Range | 3.02 - 3.63 |
| 52-Week Range | 3.02 - 665.00 |
| Beta | 0.19 |
About NDRA
ENDRA Life Sciences Inc. develops technology for improving the capabilities of clinical diagnostic ultrasound. The company develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood in the body for use in the treatment of nonalcoholic fatty liver disease, as well as in temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. It also offers diagno...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Jun 30, 2017
Employees 21
Stock Exchange NASDAQ
Ticker Symbol NDRA
Website https://www.endrainc.com
Analyst Forecast
According to 1 analyst ratings, the average rating for NDRA stock is "Buy." The 12-month stock price forecast is $14000, which is an increase of 447184.35% from the latest price.
Stock Forecasts5 months ago
-14.18%
ENDRA Life Sciences shares are trading lower. The ...
Unlock content with
Pro Subscription
5 months ago
+89.02%
ENDRA Life Sciences shares are trading higher after the company announced the activation of a post market clinical study of the TAEUS liver system.
